3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Stomach Neoplasms
12
Colorectal Neoplasms
10
Adenocarcinoma
6
Breast Neoplasms
5
Pancreatic Neoplasms
4
Neoplasm Metastasis
4
Esophageal Neoplasms
4
Sarcoma
2
Salivary Gland Neoplasms
2
Prostatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Endometrial Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Rectal Neoplasms
1
Neoplasm, Residual
1
Mouth Neoplasms
1
Interventions
pembrolizumab
3
Taxes
2
Radiotherapy
2
Polymerase Chain Reaction
2
Nivolumab
2
Nicotine
2
Magnetic Resonance Spectroscopy
2
Gene Expression Profiling
2
Fluorouracil
2
Fluorodeoxyglucose F18
2
Counseling
2
Cisplatin
2
Bupropion
2
trastuzumab deruxtecan
1
motexafin gadolinium
1
mogamulizumab
1
fluoromisonidazole
1
durvalumab
1
brodalumab
1
belinostat
1
Zinc Oxide
1
Varenicline
1
Tobacco Use Cessation Devices
1
Tadalafil
1
Surgical Procedures, Operative
1
Sucralfate
1
Specimen Handling
1
Salts
1
Rubidium-82
1
Ritonavir
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Mouth Neoplasms
×
trastuzumab deruxtecan
×
Gastrointestinal
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled